All In Biotech

Drug Trial Radar · NCT01004016

A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD

Last checked: Nov 19, 2026Latest source record: Sep 28, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Planned (sponsor's estimate)

Start

Not stated

Primary completion

Not stated

Sponsor

Sponsor type
Industry
First posted
Oct 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of KPS-0373 in patients with SCD.

Conditions

  • Spinocerebellar Degeneration

Interventions

  • KPS-0373Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Scale for Assessment and Rating of Ataxia (SARA)Time frame: 4 weeks + 12 weeks
  2. Upper and lower extremity functionTime frame: 4 weeks + 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Japan

    Japan, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.